The Impact of HER2 Overexpression on the MiRNA and CircRNA Transcriptomes in Two Breast Cell Lines and Their Vesicles
Overview
Pharmacology
Authors
Affiliations
HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and circRNAs in the cell-lines HB4a and C5.2, where the latter is a HER2-overexpressing clone of the former, and also from two different populations of their secreted extracellular vesicles. Whereas circRNA-levels were stable, we found at least 16 miRNAs apparently modulated by HER2-expression. The miR223-3p, miR-421 and miR-21-5p were validated in an independent cohort of 431 breast cancer patients from The Cancer Genome Atlas (TCGA). The consistent modulation of these molecules and their possible involvement in the HER2-axis makes them promising new targets to overcome HER2-activation.
EV-miRNA-Mediated Intercellular Communication in the Breast Tumor Microenvironment.
Sepulveda F, Mayorga-Lobos C, Guzman K, Duran-Jara E, Lobos-Gonzalez L Int J Mol Sci. 2023; 24(17).
PMID: 37685891 PMC: 10487525. DOI: 10.3390/ijms241713085.
Murillo Carrasco A, Otake A, Macedo-da-Silva J, Feijoli Santiago V, Palmisano G, Andrade L Int J Mol Sci. 2023; 24(16).
PMID: 37629204 PMC: 10455604. DOI: 10.3390/ijms241613022.
The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective.
Fogazzi V, Kapahnke M, Cataldo A, Plantamura I, Tagliabue E, Di Cosimo S Cancers (Basel). 2022; 14(21).
PMID: 36358746 PMC: 9657949. DOI: 10.3390/cancers14215326.
Yi Y, Wu M, Zeng H, Hu W, Zhao C, Xiong M Front Oncol. 2021; 11:738945.
PMID: 34707990 PMC: 8544822. DOI: 10.3389/fonc.2021.738945.
Goricar K, Dolzan V, Lenassi M Front Pharmacol. 2021; 12:671298.
PMID: 33995103 PMC: 8120271. DOI: 10.3389/fphar.2021.671298.